Depression as prognostic indicator of survival, nutritional status in head and neck cancer
the ONA take:
Presence of depression can have a significant impact on patient quality of life and treatment outcomes. This study evaluated the association between presence of pretreatment depression and pretreatment quality of life (QOL), nutritional status, and survival outcomes in patients with head and neck squamous cell carcinoma (HNSCC).
The researchers enrolled 241 patients with previously untreated HNSCC who underwent curative treatments. The Beck Depression Inventory (BDI)-II was used to determine depressive (score ≥14) vs. nondepressive (score <14) patients.
Participants also completed the European Organization for Research and Treatment of Cancer (EORTC) 30-item Core QOL Questionnaire (QLQ-C30) and the EORTC QLQ Head and Neck module (QLQ-H&N35).
Univariate and multivariate analyses were used to assess whether presence of depression was associated with overall survival, disease-free survival (DFS), or posttreatment changes in nutritional status and laboratory data.
Pretreatment depression was present in 60 patients. Study findings showed 3-year overall survival rates, 3-year DFS rates, and pretreatment serum albumin levels were lower in the depressive patients.
EORTC QLQ-C30 and QLQ-H&N35 scores differed between depressive and nondepressive patients on all items except feeding tube, nutritional supplement, and problem with mouth opening.
The researchers conclude that pretreatment depression has a significant impact on pretreatment QOL, nutritional status, and survival outcomes in patients with HNSCC.
Presence of depression can have a significant impact on patient quality of life and treatment outcomes.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|